Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Springworks Therapeutics Inc (NQ: SWTX ) 31.83 -1.00 (-3.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Springworks Therapeutics Inc < Previous 1 2 Next > FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN August 28, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 07, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors July 29, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 July 23, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/30 November 30, 2023 Via Investor Brand Network SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/28 November 28, 2023 Via Investor Brand Network SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN July 01, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference May 08, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates May 02, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 April 18, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN March 04, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors February 29, 2024 Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in... From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates February 27, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Present at Upcoming Investor Conferences February 22, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares December 08, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock December 05, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock December 04, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors November 27, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN November 16, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 02, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting November 01, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer September 11, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights August 02, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.